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Juvenile systemic sclerosis (jSSc) is an orphan disease. Currently the majority of jSSc cohort 
studies are retrospective in design without standardised assessment.  
This study was conducted prospectively to investigate the difference in manifestations of 
limited cutaneous (lcjSSc) and diffuse cutaneous (dcjSSc) subtypes. An additional aim was 
to compare these data to other historic jSSc cohorts and a large established adult onset SSc 
cohort. 
Methods:  
Patients fulfilling the PRES jSSc-classification criteria were included. Clinical characteristics 
and patient related outcomes were assessed. 
Results:   
Eighty patients were enrolled, 72.5% with dcjSSc with a mean modified Rodnan Skin Score 
(mRSS) of 18(SD), and 27.5% lcjSSc with mean mRSS of 9(SD). Mean disease duration at 
enrolment was 3.7 and 3.0 years in dcjSSc and lcjSSc patients, respectively. The mean age 
at onset of Raynaud’s and first non-Raynaud’s symptoms was similar in both groups, 
approximately 9 and 10.5 years old, respectively. Active digital tip ulcerations were present 
in 29% dcjSSc and none in the lcjSSc subjects(p=0.005). Of those with cardiopulmonary 
testing, 3% of dcjSSc and 32% of lcjSSc group had cardiac involvement (p=0.024), and 41% 
dcjSSc and 22% of the lcjSSc group had pulmonary involvement (p=0.009). Physician global 
disease damage assessment was higher in the dcjSSc compared to the lcjSSc group, 35 
and 15 respectively (p=0.021).  
Discussion:  
The majority of this international jSSc cohort had diffuse cutaneous disease (72.5%), which 
associated with more frequent vascular and pulmonary involvement compared to the limited 
cutaneous group, who had increased cardiac involvement. Our cohort reflects prior findings 
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of published jSSc cohorts and emphasizes a difference in the presentation compared to 
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Juvenile systemic sclerosis (jSSc) is an orphan autoimmune disease. The estimated 
incidence rate is 0.27 (95% CI 0.1-0.5) per million children according to a cross-sectional 
study by Herrick et al.(1). The estimated prevalence is 3 per million children based on data 
from the US claims data base (2) . To date, there has been a low number of studies 
characterising the clinical features of jSSc. In addition, the majority of published case series 
have been retrospective. The exception is the prospective jSSc cohort from the University 
of Pittsburgh(3). The two largest retrospective cohorts include 153 (4) and 135 jSSc 
patients(5), respectively. Both cohorts are multicentre and multinational cross-sectional 
surveys with cross-sectional chart review in design. Additionally, there are also some smaller 
monocentric retrospective cohorts reported (6-8). The assessment of organ involvement 
was not standardized in most of these studies and differs across the studies.  
We present data of our cohort enrolling jSSc patients who were assessed by a 
standardized protocol at time of enrolment, reflecting good clinical practice. We provide a 
summary characterization of demographic and organ manifestations, with a focus on the 
differences between the diffuse and limited cutaneous subtypes of jSSc within this cohort 
and compare these findings to the literature.   
 
Methods 
Study procedure. The coordinating study centre of the jSSc inception cohort is based 
at the Hamburger Centre of Paediatric and Adolescent Rheumatology. Initially the study was 
planned to enrol only patients with new onset jSSc, a disease duration of less than 18 
months after onset of first non-Raynaud´s organ involvement and the patient fulfilling the 
PRES classification criteria for jSSc (9). Patients have to be under the age of 18 years at 
time of the inclusion into the cohort. The cohort started enrolment in January 2008, but due 
to slow recruitment the inclusion criteria were modified in 2014 to include all patients 
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diagnosed with jSSc (9), irrespective of the disease duration. The study was continuously 
advertised at international meetings and through the paediatric rheumatology mailing list. 
The included patients are prospectively followed every 6 months for at least 60 months with 
a standardised assessment. Approval from the coordinating ethical review board for this 
project was received in 2007, with an amendment addressing the expanded inclusion criteria 
approved in May 2014. The enrolment period for this publication was from January 2008 to 
April 2016.  
 Measurements. Patient’s sociodemographic characteristics, comorbidities, and SSc 
clinical characteristics were collected at baseline. This study was conducted under minimal 
financial support. Therefore, there was no opportunity to conduct teaching sessions for 
standardization of assessments. Organ involvement was assessed using a standardized 
clinical research form (CRF) for each organ system. Patients were classified into diffuse 
(dcSSc) and limited cutaneous subset (lcSSc) (10). ANA positivity was defined as ANA > 
1:80. Anti-Scl70 and anti-centromere and other extractable nuclear antigens (ENA) 
antibodies were also assessed. Elevated ESR was defined as ESR > 20 mm/hr. Elevated 
CRP was defined by CRP > 5mg/L. 
  
Forced vital capacity (FVC) and diffusing lung capacity for carbon monoxide (DLCO) were 
considered decreased when < 80% of expected value was recorded. Pulmonary 
hypertension (PH) was screened by echocardiogram via estimates of pulmonary artery 
pressure by measuring the tricuspid regurgitation velocity (< 2.8m/s normal). Interstitial lung 
involvement was considered, if FVC was decreased < 80% and/or high resolution computed 
tomography (HRCT) of the lungs showed signs of interstitial lung disease, and other causes 
of FVC decrease were excluded by the treating physician. Cardiac involvement was defined 
as an abnormal echocardiogram finding, such as pericardial effusion, abnormal ejection 
fraction, left ventricular (LV) or right ventricular (RV) diastolic dysfunction, or abnormal ECG 
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finding. Renal involvement was considered, when there was a history of prior hypertension, 
hypertension was present at the baseline visit, or when a positive urinary sediment with 
significant proteinuria or renal crisis occurred prior or at the time of enrolment. Renal crisis 
was defined as acute severe hypertension (>150/85), acute renal failure (> 30% reduction 
in estimated glomerular filtration rate), microangiopathic haemolytic anaemia and an 
elevated creatinine (11). Gastrointestinal involvement was assessed by reported symptoms: 
diarrhoea (> 3 stools/day), constipation (stooling < than once every 3 days), reflux 
symptoms, and by evaluation with barium swallow, oesophageal scintigraphy, endoscopy 
and colon scintigraphy based on the decision of the treating clinician. Skin involvement was 
assessed by the modified Rodnan Skin score (mRSS) (12). Nailfold capillary changes were 
assessed by different methods, including dermatoscope and microscope, and it was queried 
as normal or abnormal, and the pattern could be commented (13). Musculoskeletal 
involvement was clinically assessed by total joint count and assessment of muscle strength. 
All organ evaluation methods were conducted locally at the discretion of the treating 
physician.  
 
Patient reported outcomes. Patient related outcomes included several visual analogue 
scales (VAS), scores 0 to 100, regarding the impact of the disease on the patient in regard 
to global disease activity, global disease damage, Raynaud’s activity and ulceration activity. 
Patient/parent assessment of functional ability was collected through the childhood health 
assessment questionnaire (CHAQ). 
  
Physician assessment: Physician global assessment via VAS scales, scores 0 to 100, were 




Statistical analyses. Statistical analyses were conducted using SAS software version 
9.4. Categorical variables were reported by absolute and relative frequencies, continuously 
distributed variables by means and standard deviations. Comparison between patients with 
diffuse and limited cutaneous subtype of jSSc were performed using Chi2-test for categorical 
variables and linear regression analysis for continuously distributed variables, with robust 
estimated standard errors for the regression coefficients. A p-value of <0.05 was considered 




A total of 80 patients from 26 participating centers from 17 countries were enrolled. The 
geographic distribution of the centers includes 16 from Europe, 4 from South America, 2 
from North America, and 4 from Asia. The characteristics of the patients are summarized in 
Tables 1 – 9. Patient demographics and the subtype distribution are summarized in Table 
1. Fifty-eight patients (72.5%) were classified as dcSSc and 22 as lcSSc (27.5%). Patients 
with overlap features were included within the dcjSSc and lcjSSc groups, 6 within the dcSSc 
and 5 within the lcSSc.  
The majority of subjects were Caucasian females in both the dcSSc and lcSSc subtypes 
(Table 1). The mean age at onset of Raynaud´s symptoms was 9.0 years in the dcjSSc and 
10.4 years in lcjSSc group (p=0.446), and the mean age at onset of first non-Raynaud´s 
symptom was 9.4 in dcjSSc and 10.9 in lcjSSc (p=0.30). The mean disease duration at time 
of enrolment was 3.7years in the dcjSSc and 3.0 years in lcjSSc subjects, with a mean age 
at enrolment of 13,1 years (dcjSSc) and 13.9 years (lcjSSc), respectively.   
Growth parameter assessment of the total cohort (n =80) using standardized scores for 
paediatric age and sex showed 18% had a BMI > 2SD below the mean, 36% had a height 
> 2 SD below the mean and 39% had a weight > 2SD  below the mean. Tanner 
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developmental stages were age appropriate. 
 
Laboratory evaluation and antibody profile  
ANA positivity was present in 79% and 76% of the dcjSSc and lcjSSc patients tested for 
ANA positivity. The frequency of anti-Scl 70 was similar in both groups, approximately 30%, 
while there was a difference in the anti-centromere positivity, 6% in the dcjSSc and 15% in 
the lcjSSc. Antibodies to other specific ENA’s, such as -RNA Polymerase III, Pm-Scl, and 
Th/To were not assessed. General inflammatory markers, such as erythrocyte 
sedimentation rate and C-reactive protein, were not commonly elevated (Table 1).  
 
Organ manifestations 
Skin and vascular changes. The mRSS at enrolment (Table 1) was 18.2 in the dcjSSc and 
9.1 in lcjSSc (p=0.004). Capillary abnormalities were found in in 62% in the dcjSSc and 55% 
in the lcjSSc patients (Table 1). Data were limited to provide summary results regarding 
nailfold capillary pattern. History of fingertip ulceration was fairly common in dcjSSc (60%), 
compared to 23% in lcjSSc (p=0.068), with active open ulcerations in one-third of the dcjSSc 
and none in the lcjSSc group (p=0.005).   
Cardiopulmonary disease was assessed by ECG, cardiac ultrasound, HRCT and/or 
pulmonary function tests. There were no patients with documented cardiac MRI. The 
frequency of testing is documented in Table 2, which was limited in part due to young age 
of testing. In general, 70% of the jSSc patients had an ECG, 60% had an echocardiogram, 
60% had PFTs with FVC, only 35% with DLCO, and 56% with HRCT performed. Seven of 
18 patients with FVC under 80% had a proven ILD on HRCT, 6 of the 16 in the diffuse 
subtype group and one of 2 in the limited subtype group. Interstitial lung disease was 
identified by HRCT in 56% (n=18) dcjSSc subjects and 23% (n=3) in lcjSSc group (p=0.128) 
in those with imaging. Decreased FVC%, less than 80 % predicted, occurred in 44% in the 
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dcjSSc and in 15% in lcjSSc (p=0.180). The DLCO parameter of the PFTs was assessed 
less frequently (n=28 of total cohort), it was lower than 80% predicted in approximately 50% 
of both diffuse and limited jSSc subjects. The mean distance walked in the 6 Minute walk 
test was 392 m in the dcjSSc group and 504 m in the lcjSSc group (p=0.391), however, this 
information was only available in 21 patients (Table 2).   
Any cardiopulmonary involvement, defined as either cardiac involvement, pulmonary 
hypertension or interstitial lung disease, occurred in 47% of the dcjSSc and 55% in the 
lcjSSc patients, given constraints of those tested. While cardiac involvement was more 
prevalent in lcjSSc than in dcjSSc (32% vs. 3%), pulmonary involvement was more common 
in dcjSSc, than in lcjSSc (41% vs. 23%) (Table 2). The most common cardiac manifestations 
were conduction abnormalities, which occurred in 2 dcjSSc (1st degree AV block, incomplete 
RBBB) and 4 lcjSSc (2 sinus arrhythmias, atrial arrhythmia, supraventricular extrasystole) 
patients, followed by 1 lcjSSc subject each with the following: pericarditis, mitral insufficiency 
and tricuspid insufficiency.  
The frequency of PH detected in those with echocardiograms performed was 14%(n=4) in 
dcjSSc and 13%(n=1) in lcjSSc (Table 2). No data on right heart catheterization was 
reported.  
Renal involvement (Table 3); no patients had hypertension at the initial visit or had a history 
of SSc renal crisis prior to enrolment.   
Gastrointestinal involvement (Table 3) was assessed by specific tests in 45% in the dcjSSc 
and 50% in the lcjSSc group based on the treating clinician’s judgment. Of those with 
diagnostic testing, gastrointestinal involvement was present in 38% of dcjSSc and 18% of 
lcjSSc group (p=0.212), with the majority having oesophageal involvement in both groups. 
The most commonly used assessment was barium swallow. Approximately one-third of the 
subjects had other GI manifestations, such as diarrhoea and constipation. 
Musculoskeletal involvement (Table 4) was present in 58% in dcjSSc and 73% in lcjSSc 
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group. In both subsets, joint contractures dominated with 42% in dcjSSc and 55% in lcjSSc 
(p= 0.542), while swollen joints were rarely observed. Muscle weakness occurred in 17% in 
the dcjSSc and 27% in the lcjSSc group (p=0.553), and CK was elevated in 21% in the 
dcjSSc and in 8% in the lcjSSc group (p=0.36). Only in 2 patients with dcjSSc were CK 
elevation coincident with muscle weakness, 6 patients had muscle weakness without any 
CK elevation.  
Neurologic involvement was observed in only one patient in each subset; a dcSSc patient 
with carpal tunnel syndrome, and a lcSSc patient with a demyelinating sensorimotor axonal 
polyneuropathy.  
 
Patient reported outcomes and global assessment 
The mean patient global disease activity score assessed by a visual analogue (VAS) score 
(0-100) was 44 in the dcjSSc and 46 in lcjSSc (Table 5). The mean patients’ global disease 
damage was 42 in the dcjSSc and 34 in lcjSSc (p=0.482). Raynaud’s activity assessed by 
a VAS score (0-100) was 32.0 in the dcjSSc and 21 in the lcjSSc group (p=0.525). Patients’ 
ulceration activity assessed by a VAS score (0-100) was 19 in the dcjSSc and 11 in the 
lcjSSc group (p=0.355).  The mean CHAQ score was 0.4 in both subtypes. 
 
Physician global assessment 
Table 5 describes the physician global assessments. The disease activity global and digital 
ulcers VAS assessments were not significantly different between the dcjSSc and lcjSSc 
groups, while the global disease damage physician assessment was significantly higher in 
the dcjSSc group (35 vs. 15; p=0.021). In the lcjSSc group patients/parents judged the 
disease activity and disease damage higher than the treating physician (Table 5). 
 
SUBANALYSES OF COHORT 
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Differences in the clinical presentation according gender 
A subanalysis was performed to examine for gender differences.  Results are described in 
Table 6.  The majority of the cohort was female (82.5%). Dichotomizing the cohort into male 
and female demonstrated similar predominance of dcSSc seen in the total cohort (72%), as 
well as similar disease onset and duration, although the male patients were slightly younger 
at the presentation of the first non-Raynaud´s with a mean of 9.1 years versus 10.0 years of 
age.  Clinical variables were assessed between the two sexes for differences. The majority 
of organ manifestations were similar; however, there were a few clinical items that 
demonstrated a significant difference, pointing towards more severe disease in male 
patients compared to female patients. These include the 6 minute walk distance 
(268.7m/441.4m; p=0.035), number of patients with musculoskeletal involvement 
(92.9%/55.4%; p=0.009), number of patients with joint contractures (78.6%/38.1%; p=0.006) 
and number of patients with tendon friction rubs (33.3%/6.7%; p=0.013) (Table 6).  There 
were significant differences regarding the patient related outcomes and physician global 
assessment also between male and female patients, including physician global disease 
activity (58.3%/34.3%; p=0.037), physician global disease damage (68.3%/26.2%;p=0.001) 
and patient related disease damage (58.3%/41.9%;p=0.041)(Table 6.). 
 
Differences in the clinical presentation according anti-Scl70 positivity and  anti-Scl70 
negativity 
In both dcSSc and lcSSc subjects, approximately 30% of the patients are anti-Scl70 positive. 
A subanalysis dichotomizing the cohort into anti-Scl70 positive vs. negative was performed 
to evaluate if certain clinical features are more strongly associated with Scl70 antibody 
positivity in jSSc. Results are summarized in Table 7.  Approximately 70% of the patients 
were classified as diffuse subtype in both groups.  There is no significant difference between 
the groups regarding demographics, age of onset or disease duration at the time of entering 
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the cohort (Table7). Only a few clinical variables differed significantly between the Scl70 
positive and negative patients.  This included a higher CRP in the anti-Scl70 group 
(35%/8.5%; p=0.007), and a higher percentage of those with an abnormal HRCT 
(58.1%/23.1%, p=0.034) and number of joints with decreased range (57.7%/29.2%; 
p=0.021) in the anti-Scl 70 negative group (Table 7). 
 
Differences in clinical presentation according at age under 10 years or over 10 years 
at the time of inclusion in the cohort. 
To examine if a younger age of onset within the jSSc cohort has an impact on clinical 
features a subanalysis was performed comparing those enrolled into the cohort under the 
age of 10 years (n=16) vs 10 years or older (n=64) (Table 8).  Although not reaching 
statistical significance, the proportion of patients with diffuse subtype is much higher under 
the age of 10, with 87.5% having dcSSc, compared to the overall cohort (72%), and >10 
years onset (68%).  More overlap features were present in the older age group.  The mean 
age of onset was significantly lower in the under 10 years group, with 4.3 years compared 
to 11.00 years (p=0.027), as expected, though with a longer disease duration until enrolment 
in the older subgroup, 3.9 vs. 2.9 years.  Two clinical characteristics varied significantly 
between the two groups, the number of patients with telangiectasias (54.5%/21%; p=0.03) 
and with gastrointestinal involvement beside oesophageal involvement (12.5%/1.6%; 
p=0.039), both being more prevalent in the younger age group.  The judgment of the 
physician regarding global disease activity was significantly higher in the younger patients 
(57.9/33.7; p=0.037) (Table 8). 
 
Treatment at the time of inclusion into the cohort 
Medication at the time of enrolment was available for 86% of the cohort and are described 
in Table 9.  In general, over half were on corticosteroids and/or methotrexate, followed by 
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mycophenolate mofetil and hydroxychloroquine regarding DMARD therapy, with only 3 
patients on a biologic DMARD. Calcium channel blockers were the most common 
vasodilator utilized (40%), followed by a variety of vasodilator agents. 
 
Discussion 
We present enrolment data of the first 80 patients included in our prospective international 
jSSc registry. Given the estimated low incidence rate of jSSc, our cohort of 80 patients is 
sizable. Interestingly, compared to adult patients, where approximately 30 to 40% have 
diffuse subset (14, 15), we report a higher proportion of patients with dcjSSc (72.5%). This 
number is between two previously published paediatric cohorts with 90% (4) and with 35% 
(3). (Table 10). This subset distribution seems to be a characteristic of the paediatric 
patients, with the predominance of the diffuse subset demonstrated even more vividly in 
those with younger age of onset in our subanalysis (81% in those <age 10 at enrolment). 
Organ involvement was similar in this young group of dcjSSc compared to older onset jSSc. 
The auto-antibody profile in jSSc might not correlate as strongly to cutaneous disease 
subtype as there was an equal amount of subjects with positive anti-topoisomerase (30%) 
in the lcSSc and dcSSc groups, which is more classically associated with dcSSc subtype in 
adult SSc. As seen in prior jSSc cohorts, anti-centromere positivity has a low frequency in 
jSSc (3-5).  This ‘crossing over’ of autoantibodies between classical subsets is demonstrated 
in adult SSc patients in a similar frequency, as described in the large EUSTAR cohort of 
7655 patients(16), where 23% of lcSSc patients have anti-Scl70 positivity and 7.2% of the 
dcSSc patients have anticentromere positivity. The caveat in jSSc is the overall lack of 
identified specific autoantigens. Most jSSc cohorts will demonstrate a high ANA positivity, 
but typically 40% or less have combined Scl-70 or centromere positivity (3, 4), therefore, 
basing certain clinical features with autoantibody positivity may be limited. Our subanalysis 
evaluating for differences in clinical presentation in anti-Scl70 positive and negative 
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paediatric patients found surprisingly a significantly higher number of patients with interstitial 
lung disease in the anti- Scl 70 negative group. 
In the paediatric population, the female to male ratio is much less dramatic, with 4.8:1 in the 
dcjSSc and 3.4:1 in the lcjSSc group, compared to the adult SSc population with a 6:1 
ratio(17), 4:1 for dcSSc and 10:1 for lcSSc (16).  In the younger age group, we found an 
even lower ratio of 3:1, which would suggest that hormonal influence in the puberty and after 
in adult females is a risk factor to develop SSc. In adult SSc male patients tend to have a 
more severe disease(17). We confirmed this observation in jSSc, finding significantly higher 
rating for physician global disease activity, physician global disease damage and patient 
rating of physician global disease activity. Clinical features more prevalent in jSSc males 
include musculoskeletal domains of weakness, joint contractures and tendon friction rubs. 
The gender gap described in the large EUSTAR cohort also observed significant 
musculoskeletal burden in males compared to females, characterized by muscle atrophy 
and CK elevation (18)(19). 
 Despite the preponderance of dcSSc disease subtype in this jSSc cohort compared to adult-
onset SSc, renal crisis was not observed in our cohort with a mean disease duration of 3.5 
years, compared to 4 to 6% frequency in adult patients (16, 20). We also found a lower rate 
of patients with CRP elevations than expected in an adult population, where one-quarter of 
the patients have CRP elevation (16, 21), especially early in the disease course. Interestingly 
anti-Scl70 positivity correlates with elevated CRP in our cohort. 
Within our juvenile-onset SSc cohort, we observed a few main differences between the 
diffuse and limited subsets. This includes a higher mRSS, more frequent active ulcerations 
and pulmonary involvement (mainly consisting of ILD identified by HRCT) in the dcSSc 
subjects, which mirrors adult SSc cohort data(22). On the contrary, a higher frequency of 
cardiac involvement was reported in the lcjSSc subjects, consisting mostly of conduction 
defects. These subjects tended to also have musculoskeletal organ involvement, supporting 
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an underlying myopathy of both peripheral muscle and cardiac skeletal muscle as 
demonstrated by Scalapino et al(3) jSSc cohort and Quartier et al observations in jSSc (22). 
The frequency of suspected pulmonary hypertension by echocardiography, around 7%, was 
similar between the two subsets, and in the other large paediatric cohorts (Table 10) 
whereas, in adult SSc it is approximately 20% (16). Although our findings are only a 
reflection of the true frequency in these subtypes as cardiac and pulmonary testing was not 
obtained on all subjects.  
This is the first prospective study in a large international jSSc patient population, where 
patient reported outcomes and physician global assessment data are reported. We 
demonstrated significantly more damage impact in dcjSSc compared to lcjSSc patients 
when physicians globally score the patient, presumably physician rating is strongly 
influenced by the mRSS and the higher ulceration activity. Of interest, children interpret a 
higher disease activity and severity impact on their VAS compared to the physician’s treating 
them, especially in the lcSSc subtype. jSSc overall does have a more severe impact on 
general function, as measured by the universally validated and accepted CHAQ instrument, 
with a mean CHAQ score of 0.4, which is in the same range as JIA patients before starting 
anti-TNF therapy (23),  higher than JDM (0.25) (24) and jSLE (0.25) (25)  captured in the 
CARRA cohort. 
There are several prospective SSc registries for adult patients (26), but ours is the first 
multicentre international prospective registry in paediatrics with standardized data collection 
forms, including current assessment methods. The only large prospective paediatric study 
including 111 patients collected from 1960 to 2003, is single centre based study, and the 
evaluation methods of the patients’ organ involvement over such large time period changed 
significantly (3). 
The secondary aim of this publication was to compare our findings with other historic large 
paediatric-onset SSc cohorts (3-5), which are summarized in Table 10. Since our jSSc 
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cohort was predominantly dcSSc subtype, a large EUSTAR adult-onset SSc cohort that 
contains a large dcSSc patient population was chosen as a comparison(16) (Table 10). 
The age of onset, disease duration, female:male ratio, and ethnicity is comparable to other 
historic jSSc cohorts (3-5). Joint involvement in the paediatric cohorts ranges from 27 to 
82%, our cohort in the middle range with 42.4%, similar in range as the adult comparison. 
Raynaud’s is almost universal in all paediatric jSSc cohorts (3-5), the higher frequency of 
nailfold capillary abnormalities and digital ulcers in our cohort is likely secondary to the 
emphasis placed on these variables in the CRFs, reaching closer to true frequency, which 
also matches the adult populations. On the other hand, the gastrointestinal involvement is 
lower in our cohort, we surmise secondary to the low number of patients with formal GI 
investigation (46%). We continue to observe less patients with decreased DLCO, FVC and 
pathologic HRCT of the lung in the paediatric cohorts (Table 10). PH occurs in 7% of the 
paediatric patients across all cohorts, compared to 22% in the adults. Renal involvement is 
low in all jSSc cohorts (4-13%), with renal crisis being extremely rare (<4%). Interestingly, 
hypertension is very low or not observed in the paediatric patients. This could be explained 
by the missing comorbid conditions in this age group. Muscular involvement ranges from 10 
to 32% in the paediatric patients and has been associated with cardiac involvement in the 
Scalapino(3) cohort as in our cohort.  
Our study provides some very unique and interesting blanket of data on jSSc subjects early 
in the disease course with a mean disease duration of 3.5 years. However, the study has 
limitations. The results may be interpreted with some caution due to the small sample size 
and in particular in subgroup analyses. This is a cohort study and the participating clinicians 
report according their standard of care in jSSc in the CRF. Performance of additional organ 
evaluation was not mandatory due to the observational study design and ethical reasons. In 
consequence, the results of specific organ manifestation screenings include a remarkable 
proportion of missing data and may be slightly biased to patients with a more severe organ 
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involvement; however, the similarity of organ involvement pattern compared to other jSSc 
cohorts is reassuring.  
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Table 1. Clinical characteristics of the patients at the time of inclusion into the 
cohort: 





























Ethnicity:     
     Caucasian  71 (89%) 51 (88%) 20 (91%) 0.710 
     African 4 (5%) 4 (7%) 0 (0%) 






3.7 (3.2) 3.0 (2.5) 0.590 
Mean age of onset 
of Raynaud´s 




9.0 (3.8),   
5 non-
Raynaud 




Mean age of onset 
of non-Raynaud´s 
(years), mean (sd) 
9.9 (4.1) 9.4 (3.7) 10.9 (4.6) 0.300 
     
Autoantibody 
positivity: 
    
ANA  78% (60/77) 79% *(44/56) 76% *(16/21) 0.937 
Anti-Scl 70  31% (24/77) 30% (17/56) 33% (7/21) 0.856 
Anti-centromere 9% (4/46) 6% (2/33) 15% (2/13) 0.363 
Inflammatory 
markers: 
    
ESR elevated  
(>20 mm/hr) 
26% (20/76) 30% (17/57) 16% (3/19) 0.344 
CRP elevated  16% (11/70) 17% (9/52) 11% (2/18) 0.590 
 22 
(>5 mg/l)  
Cutaneous:     
Mean modified 








Vascular:     
Raynaud´s 
phenomenon 
90% (72/80) 91% (53/58) 86% (19/22) 0.878 
Nailfold capillary 
changes 
60% (48/80) 62% (36/58) 55% (12/22) 0.757 
History of ulceration  50% (39/78) 60% (34/57) 23% (5/22) 0.068 



























81% (65/80) 78% (45/58) 91% (20/22) 0.666 
ECG done 71% (57/80) 67% (39/58) 82% (18/22) 0.605 
Cardiac US done 59% (47/80) 50% (29/58) 82% (18/22) 0.206 
FVC done 60% (48/80) 62% (36/58) 55% (12/22) 0.757 
DLCO done 35% (28/80) 33% (19/58) 41% (9/22) 0.640 
HRCT done 56% (45/80) 55% (32/58) 59% (13/22) 0.868 
Pulmonary:     
FVC < 80%  37% (18/48) 44% (16/36)  15% (2/12) 0.180 
DLCO < 80% 53% (15/28) 53% (10/19) 56% (5/9) 0.937 




392.6m    
(141) n=16 





Assessed by HRCT 
47% (21/45)  56% (18/32)  23% (3/13) 0.128 
Total Pulmonary 
involvement 
36% (29/80) 41% (24/58) 22% (5/22) 0.009 




assessed by US 
 11% (5/47)  14% (4/29)  13% (1/18) 0.603 
Total Cardiac 
involvement 




Table 3. Clinical characteristics of the patients at the time of inclusion into the 
cohort: 












subtype       
 
N=22 




Renal:     
Assessed by urine 
test 
6% (5/80) 7% (4/58) 5% (1/22) 0.714 
Proteinuria 4 4 0 -- 
Erythrocyturia   1 0 1 -- 
Hypertension 
Assessed by RR 
0% (0/80) 0% (0/58) 0% (0/22) -- 
Gastrointestinal:     




46% (37/80) 45% (26/58) 50% (11/22) 0.803 
Endoscopy done 15% (12/80) 17% (10/58) 9% (2/22) 0.425 
Oesophageal 
scintigraphy done 
9% (7/80) 7% (4/58) 14% (3/22) 0.389 
Barium swallow 
done 
26% (21/80) 24% (14/58) 32% (7/22) 0.599 
Colon scintigraphy 
done 











 69% (18/26)  68% (15/22) 75% (3 /4) 0.909 
GI beside 
oesophageal 
 31% (8/26)  32% (7/22) 25% (1/4) 0.093 
 25 
 
Table 4. Clinical characteristics of the patients at the time of inclusion into the 
cohort: 








Limited subtype      
N=22 




Musculoskeletal  62% (49/79)  58% (33/57)  73% (16/22) 0.563 
Joint Manifestation:     
Number of patients 
with swollen joints  
 35% (17/49)  36% (12/33)  31% (5/16) 0.724 
Number of joints with 
pain on motion  
 43% (21/49)  39% (13/33)  50% (8/16) 0.482 
Number patients 
with contractures  
45% (35/77) 42% (23/55) 55% (12/22) 0.542 
Muscle 
Manifestation: 
    




 13% (6/46)  11% (4/35)  18% (2/11) 0.616 
Muscle weakness 
with no contractures 
7% (3/46) 6% (2/35) 9% (1/11) 0.713 
     




Table 5. Clinical characteristics of the patients at the time of inclusion into the 
cohort: 

















































11 (0-57)  
n=12 
0.355 
CHAQ 0.4 (0 - 2.5) 
n=51 
0.4 (0 - 2.5)  
n=40 





38 (0-90)  
n=44 
















15 (0-83)  
n=69 
17 (0-83)  
n=56 








Table 6.   







Diffuse subtype 48 (72.7%) 10 (71.4%) 0.982 
Diffuse overlap 6 0  
Limited subtype 18 (27.3%) 4 (28.6%)  
Limited overlap 5 0  
    
Caucasian  59 (89.4%) 12 (85.7%) 0.834 
African 4 (6.1%) 2 (14.3%)  
Indian 2 (3%) 0 (0%)  
Yemenite 1 (1.5%) 0 (0%)  
    
Mean Disease duration 
(years) 
3.6 (± 3.1) 
 
3.3 (± 2.9) 
 
0.671 
Mean age of onset of 
Raynaud´s (years) 
9.4 (± 4.1) 
8 non-Raynaud 
9.3 (± 3.9) 
0 non-Raynaud 
0.913 
Mean age of onset of non-
Raynaud´s (years) 
10.0 (± 4.1) 9.1 (± 3.9) 0.834 
    





6 Minute Walk Test 
(Mean, SD) 
441.4m (±116.1)  
n=18 
286.7m (±179.8) n=3 0.035 
Musculoskeletal  55.4%  
(36/65) 
 92.9%  
(13/14) 
0.009 
Total contractures 38.1%  
(24/63) 
 78.6%  
(11/14) 
0.006 
Tendon Friction Rub 6.7% 
(4/60) 
 33.3%  
(3/9) 
0.013 
























Table 7. Clinical significant differences in the patients characteristics in the cohort 
according anti-Scl70 positivity or negativity 
 
 Anti-Scl 70 negative 
N=53 
Anti-Scl 70 positive 
N=24 
P-value 
    





    
Diffuse subtype 39 (73.6%) 17 (70.8%) 0.867 
Diffuse overlap 5 0  
Limited subtype 14 (26.4%) 7 (29.2%)  
Limited overlap 4 0  
    
Caucasian  49 (92.4%) 20 (83.3%) 0.834 
African 4 (7.5%) 2 (8.3%)  
Indian 0 (0%) 1 (4.2%)  
Yemenite 0 (0%) 1 (4.2%)  
    
Mean Disease duration 
(years) 
3.7 (± 3.1) 
 
3.4 (± 3.0) 
 
0.671 
Mean age of onset of 
Raynaud´s (years) 
9.5 (± 3.8) 
6 non-Raynaud 
9.7 (± 4.1) 
1 non-Raynaud 
 
Mean age of onset of non-
Raynaud´s (years) 
9.8 (± 4.0) 10.3 (± 4.0) 0.846 
    







































Table 8. Clinical significant differences in patient characteristics in the cohort 
according age at inclusion under age of 10 and over age of 10 years 
 
 < 10years at first visit 
N=16 
> 10years at first visit 
N=64 
P-value 
    





    
Diffuse subtype 14 (87.5%) 44 (68.7%) 0.574 
Diffuse overlap 0 6  
Limited subtype 2 (12.5%) 20 (31.2%)  
Limited overlap 1 4  
    
Caucasian  14 (87.5%) 57 (89.1%) 0.972 
African 1 (6.25%) 5 (7.8%)  
Indian 0 (0%) 2 (3.1%)  
Yemenite 1 (6.25%) 0 (0%)  
Mean Disease duration 
(years) 
2.3 (± 1.8) 
 
3.9 (± 3.2) 
 
0.539 
Mean age of onset of 
Raynaud´s (years) 
4.3 (± 2.3) 
0 non-Raynaud 
11.0 (± 3.0) 
8 non-Raynaud 
0.027 
Mean age of onset of non-
Raynaud´s (years) 
4.8 (± 2.1) 11.2 (± 3.3) 0.074 












 12.5%  
(2/16) 



















Whole group Diffuse subtype Limited 
subtype 
P value 
Number of patients 80 58 (72.5 %) 
 
22  (27.5%) 
 
 
Medication 86% (62/71) 




7 patient no data 
90% (18/20) 





61% (27/44) 50% (9/18) 
0.410 
Biologic  and nonbiologic 
DMARDs 
    
Methotrexate 56%(35/62) 54%(24/44) 61%(11/18) 0.636 
Mycophenolate mofetil 18% (11/62) 
 
18% (8/44) 17%(3/18) 
0.887 
Azathioprine 2% (1/62) 
 
2% (1/44) 0% (0/18) 
0.519 
Cyclophosphamide 8% (5/62) 
 
11% (5/44) 0% (0/18) 
0.136 
CQ/HCQ 16% (10/62) 
 
14% (6/44) 22% (4/18) 
 
0.404 



















     
Non-DMARDS     













2%(1/62) 0% (0/44) 6% (1/18) 
0.115 
Ca channel blockers 
 




25 (1/62) 0% (0/44) 6% (1/18) 
0.115 
AT1 receptor blockers 2% (1/62) 2% (1/44) 0% (0/18) 0.519 
Anti-coagulants 
 




Table 10.   Comparison of the different paediatric cohorts focused on diffuse subset 
patients, compared to a large international adult SSc cohort, EUSTAR (n= 7655) (16). 
 
 Cohorts         























et. al (3) 













Demographics          
Age onset 
(years) 
         
   Onset of RP 9.4 9.0 10.4 8.8* 8.1* 11.1* 42.2 42.2 42.1 
   Onset Non-RP 9.9 9.4 10.9 --- --- --- 45.9 44.2 47.2 
Follow up (yrs) 3.5 3.7 3.0 5.0 3.9 14.4 ND ND ND 
Sex 







































Subtype (%)          
    diffuse 
(dcSSc) 
72.5 --- --- ND 91 35 37.1 --- --- 
    limited (lcSSc) 22.5 --- --- ND 9 36 58.5 --- --- 








         
Skin          
   mRSS (mean) 15.7 18.2 9.1 ND ND 19.4 8 16 6 
Vascular          
    Raynaud’s 90 91 86 72 84 97 96.3 96.1 96.6 
 32 
    Nailfold  
    capillary  
    changes 
60 62 55 ND 39.9 ND 90.9 92.2 90.1 
    Digital 
infarcts    
    / ulceration 
50 60 23 28.6 29 ND 36 42.4 32.7 
MSK          
    Joint    
    contracture 
45 42 55 79 27 82 32.1 48.7 21.9 
    Muscle     
    weakness 
20 17 27 ND 24.2 32 25 33.5 18.9 
GI tract 33 38 18 65 69 74 67+ 70+ 66+ 
    Oesophageal 22.5 26 13.6 47 31 ND 67.3 69.5 66.4 
Pulmonary 36 41 22 50 42 55 60.6 64.1 52.0 
    Pulmonary     
    hypertension 
11 7 5 ND 7.2 7 21.1 22.1 20.7 
    Abnormal  
    HRCT/fibrosis 
26 31 14 ND 23.5 ND 51.9 64.1 43.5 
    Reduced 
DLCO 
19 17 22.7 ND 27.5 ND --- --- --- 
    Reduced FVC 22.5 27.5 9 ND 41.8 16 
severe 
FVC<50 
--- --- --- 
Cardiac 12 3 32 44 29 17 37.0 42.1 33.7 
Renal          
    Proteinuria 5 7 0 13 4.6 4 6.1 8.4 4.4 
    Hypertension 0 0 0 ND 2.6 4 20.6 20.3 21.2 
    Renal crisis 0 0 0 0.7 0.7 4 2.1 4.0 1.0 
Autoantibodies 
(% )positive of 
those tested 
         




5 3.4 9 ND 7.1 8 32.3 7.2 48.2 
   Anti-Scl 70 30 29 31.8 ND 34 20 36.8 59.8 23.2 
*unknown if onset RP or Non-RP; ND = Not done 
 
 
